Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian
iwNHL 2016 highlights: CAR T-cell therapy, DLBCL and new technologies
The characteristics and mode of action of ibrutinib for CLL
Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers
Naval G. Daver
Panel discussion on mantle cell lymphoma
Constantine Tam et al.